Patent Term Restoration vs. Adjustment: The $300 Billion Clock Pharma Can’t Afford to Misread
Every pharmaceutical patent starts its life with a 20-year timer running from the filing date. By the time a new […]
Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives
Every patent portfolio in the pharmaceutical industry contains dead weight. Not metaphorically — literally. Compounds whose commercial logic evaporated years
Know Before You Launch: The Complete Step-by-Step Guide to Freedom-to-Operate Analysis in Pharma
Launching a drug without a freedom-to-operate analysis is like building a factory on land you haven’t verified you own. You
Business Development Guide for Commercial & Market Access Vendors: Sell Before the Drug Patent Clock Runs Out
How to Win Biopharma Contracts by Entering the Deal Before Generic Entry Does Why Timing Is the Only Thing That
Drug Patents in Asia-Pacific: A Country-by-Country Guide to How Long Protection Actually Lasts
The Number Every Pharma Strategist Gets Wrong Ask a pharmaceutical executive how long a drug patent lasts in Asia-Pacific, and
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore
How generic drug suppliers’ litigation histories expose supply chain risk, financial fragility, and competitive staying power — before you sign
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore Read Post »
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign
A practical playbook for formulation vendors, CDMOs, and excipient suppliers on how to mine patent loss-of-exclusivity data to find, time,
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign Read Post »
Sell the Line Before the Patent Breaks: A Business Development Guide for Solid Dose Equipment & Manufacturing Technology Suppliers Targeting Pre-LOE Generic Expansion
The $200 Billion Window Nobody in Sales Talks About Between 2025 and 2030, an estimated $200 billion in annual branded
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents
How rare disease drugmakers build market protection that no generic can touch — and what every analyst needs to know
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
